BR112021005518A2 - métodos para tratar distúrbios mieloproliferativos - Google Patents

métodos para tratar distúrbios mieloproliferativos Download PDF

Info

Publication number
BR112021005518A2
BR112021005518A2 BR112021005518-5A BR112021005518A BR112021005518A2 BR 112021005518 A2 BR112021005518 A2 BR 112021005518A2 BR 112021005518 A BR112021005518 A BR 112021005518A BR 112021005518 A2 BR112021005518 A2 BR 112021005518A2
Authority
BR
Brazil
Prior art keywords
thiamine
patient
compound
myelofibrosis
equivalent
Prior art date
Application number
BR112021005518-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Tymara Berry
John Hood
Catriona Jamieson
Curtis L. Scribner
Original Assignee
Impact Biomedicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112021005518(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines, Inc. filed Critical Impact Biomedicines, Inc.
Publication of BR112021005518A2 publication Critical patent/BR112021005518A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112021005518-5A 2018-09-25 2019-09-24 métodos para tratar distúrbios mieloproliferativos BR112021005518A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
BR112021005518A2 true BR112021005518A2 (pt) 2021-06-29

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005518-5A BR112021005518A2 (pt) 2018-09-25 2019-09-24 métodos para tratar distúrbios mieloproliferativos

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) * 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
US20240058336A1 (en) 2020-12-16 2024-02-22 Impact Biomedicines, Inc. Dosing of fedratinib
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3099677A4 (en) * 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN108348578B (zh) * 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Also Published As

Publication number Publication date
WO2020068755A1 (en) 2020-04-02
MX2023013844A (es) 2023-12-08
JP2024161416A (ja) 2024-11-19
AU2019346521A1 (en) 2021-05-20
JP2022502492A (ja) 2022-01-11
SG11202103019WA (en) 2021-04-29
EP3856169A1 (en) 2021-08-04
KR20250164332A (ko) 2025-11-24
MY209349A (en) 2025-07-03
EP3856169A4 (en) 2022-06-29
AU2019346521B2 (en) 2025-05-08
IL281736A (en) 2021-05-31
MX2021003450A (es) 2021-07-16
US11400092B2 (en) 2022-08-02
MA53741A (fr) 2021-08-04
US20220133724A1 (en) 2022-05-05
CN113286584A (zh) 2021-08-20
CL2021000744A1 (es) 2021-10-08
KR20210102192A (ko) 2021-08-19
US20220031699A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US11400092B2 (en) Methods of treating myeloproliferative disorders
BR112019015011A2 (pt) combinações de cabozantinibe e atezolizumabe para tratar câncer
US20190002988A1 (en) Method of using a ret fusion gene as a biomarker to select non small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
CN120531737A (zh) 用于治疗癌症的menin-mll抑制剂
Wang et al. First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
TW202038964A (zh) 組合療法
US20220133751A1 (en) Methods of treating myeloproliferative disorders
Al‐Kali et al. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia
TW202112368A (zh) 用於治療有關dux4表現之疾病的抑制劑組合
CN113730572A (zh) 含有抗egfr抗体或其片段的联合用药物
WO2011133826A2 (en) Method for treating pancreatic cancer
CN119923258A (zh) 在wnt通路肿瘤阻抑基因中具有突变的癌症的治疗
CA3203995A1 (en) Treatment regimens with fixed doses of tamibarotene
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
Kapp et al. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells
HK40049559A (en) Methods of treating myeloproliferative disorders
JP7419572B2 (ja) 小児がん治療用医薬組成物
Yonesaka et al. Alternating therapy with osimertinib and afatinib blockades EGFR secondary mutation in EGFR-mutant lung cancer: a single-arm phase II trial
EA048287B1 (ru) Способы лечения миелопролиферативных расстройств
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023019225-7 PROTOCOLO 870230083516 EM 20/09/2023 18:07.